Elite Pharmaceuticals, Inc. — Second Quarter Fiscal Year 2027 Earnings Summary

Financial Performance:

• Consolidated revenues for the three months ended September 30, 2026, were $40.1 million, representing a $3.8 million or 10.4% increase compared to the same period in the prior fiscal year.
• Income from operations was $9.9 million, an increase of $1.7 million or approximately 21% compared to the prior year period.
• Net income attributable to common shareholders was $17.3 million for the Second Quarter.
• The revenue increase was primarily driven by higher sales from the Elite label amphetamine and naltrexone product lines.

Other Key Points:

• A conference call to discuss the results is scheduled for Friday, November 13, 2026, at 11:30 AM EST.
• Stockholder questions should be submitted in advance via email to dianne@elitepharma.com.
• Financial questions must be submitted by 7:00 PM EST on Thursday, November 12, 2026.
• Financial statements for the period are available on Form 10-Q.
• The company operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ.
• The press release includes standard forward-looking statement disclaimers regarding FDA approvals and other risks.